Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for ...
Increasing evidence suggests that the severe gum disease, periodontitis, may contribute to central nervous system disorders ...
Many people with multiple sclerosis struggle with balance and coordination, and this study uncovers a hidden reason why.
Increasing evidence suggests that the severe gum disease, periodontitis, may contribute to central nervous system disorders ...
The devastating consequences of mucopolysaccharidosis II (MPS II), also called Hunter syndrome, may soon become preventable ...
FDA grants AXS-05 Priority Review designation and sets PDUFA action goal date of April 30, 2026 NEW YORK, Dec. 31, 2025 ...
High levels of the periodontal bacterium Fusobacterium nucleatum may be associated with more severe disability in people with multiple sclerosis.
Delhi will declare human rabies a notifiable disease under the Epidemic Diseases Act to strengthen surveillance and response.
Trial design and comparator group - FDA and Plus discussed a randomized controlled trial design approach and that the study may include an intrathecal chemotherapeutic as a comparator, as well as ...
Zenas BioPharma tanks nearly 52% despite positive INDIGO study data where obexelimab cut IgG4-RD flare risk by 56% and met all key endpoints.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback